imatinib mesylate has been researched along with Cardiac Remodeling, Ventricular in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, GX; Fan, T; Hou, J; Liang, MY; Wang, LX; Wu, ZK; Yang, X; Yue, Y | 1 |
| Higuchi, M; Hikasa, Y; Leong, ZP; Okida, A; Yamano, Y | 1 |
| Chang, K; Choo, EH; Ihm, SH; Jang, SW; Kim, HY; Kim, OR; Park, CS; Seung, KB | 1 |
| Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N | 1 |
4 other study(ies) available for imatinib mesylate and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.
Topics: Animals; Cell Survival; Cells, Cultured; Echocardiography; Fibrosis; Gene Expression; Heart Diseases; Imatinib Mesylate; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Receptors, Platelet-Derived Growth Factor; Ventricular Remodeling | 2017 |
Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Indoles; Male; Monocrotaline; Nestin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyrroles; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Topics: Animals; Benzamides; Blotting, Western; Collagen Type I; Collagen Type III; Fibroblasts; Fibrosis; Gene Expression; Hypertension; Hypertrophy, Left Ventricular; Imatinib Mesylate; Male; Myocardium; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1; Ventricular Remodeling | 2014 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling | 2008 |